pushes ~$69+ on Russia fuel export curbs—keeping energy in focus while INR remains near record-weak zones on the FBIL 88.67 print. Overnight developments have intensified market concerns, particularly President Trump's announcement of 100% tariffs on branded pharmaceutical products effective…
Global tech sentiment has weakened: as Asian markets opened in red following Trump's tariff announcements, with South Korea's Kospi falling 1.9% and Japan's Nikkei declining 0.3%.
Actionable trigger: Monitor pharma sector opening reactions and any company-specific announcements regarding US manufacturing plans.
Immediate pressure points: include pharmaceutical majors facing tariff headwinds, with companies like Dr.
Global curiosity: Japan's core inflation held steady above the 2% target in September, keeping BoJ rate hike expectations alive.
pushes ~$69+ on Russia fuel export curbs—keeping energy in focus while INR remains near record-weak zones on the FBIL 88.67 print. Overnight developments have intensified market concerns, particularly President Trump's announcement of 100% tariffs on branded pharmaceutical products effective October 1, 2025. The Nifty 50 has now declined for five consecutive sessions, closing below the psychological 25,000 mark at 24,890.85 yesterday. Key watch factors today include sectoral impact assessment from the pharma tariff announcement and sustained FII outflow pressures.
Global tech sentiment has weakened as Asian markets opened in red following Trump's tariff announcements, with South Korea's Kospi falling 1.9% and Japan's Nikkei declining 0.3%. The pharmaceutical tariff specifically targets branded and patented products unless companies are actively building manufacturing plants in the US, defined as "breaking ground" or "under construction". Indian pharma stocks face particular pressure given that India supplies 45% of generic and 15% of biosimilar drugs used in the US market.
Indian startups have raised $7.7 billion in the first nine months of 2025, positioning India as the third-most funded market globally, ahead of Germany and France but behind the US and UK. Despite a 23% decline from $10.1 billion in 2024, the ecosystem shows resilience across sectors. Notable September funding includes ILJIN Electronics India raising $144 million from ChrysCapital and InCred Growth Partners, and GREW Solar securing $36 million from GeeCee Holdings. Sectoral ripple effects: Electronics manufacturing and renewable energy sectors continue attracting institutional capital, supporting India's industrial transition.
Immediate pressure points include pharmaceutical majors facing tariff headwinds, with companies like Dr. Reddy's, Cipla, and Sun Pharma likely to see opening weakness. Bank Nifty trading around 50,700 levels faces resistance at 51,000-51,200 zone. FII outflows continue pressuring broader markets, with the rupee touching fresh lows around 88.69-88.73 levels.
Indian Markets Under Pressure: 4-Day Decline Trend (Sep 22-25, 2025)
Global curiosity: Japan's core inflation held steady above the 2% target in September, keeping BoJ rate hike expectations alive. US GDP was revised up to 3.8% annualized for Q2 2025, driven by stronger business investment in data centers and GPU equipment. Defense stocks rally globally as DroneShield becomes Asia's top performer on military spending increases.
President Trump's pharmaceutical tariff strategy represents a calculated move to onshore critical drug manufacturing, targeting both generic and branded imports worth nearly $233 billion annually. The stakes are significant: Nearly 90% of US biotech companies rely on imported components for at least half of their approved products. For Indian pharma giants, this creates a strategic inflection point - companies must either absorb margin compression or accelerate US manufacturing investments. Peer comparison: European pharmaceutical companies face similar pressures, with the US-EU trade framework already imposing 15% tariffs on pharma products since July. Actionable investor takeaway: Watch for company-specific announcements regarding US facility investments and assess which Indian pharma players have existing US manufacturing capabilities.
Macro calendar: US Personal Income and Spending data, University of Michigan Sentiment Index. Earnings focus: No major Indian earnings releases scheduled. Regulatory events: Monitor RBI commentary on rupee volatility and any pharmaceutical sector guidance from industry bodies. Global cues: Asian markets performance and US futures reaction to tariff announcements.
"India's climb to the third rank globally underscored the resilience and adaptability of its startup ecosystem" - Neha Singh, Co-Founder of Tracxn, commenting on $7.7 billion funding achievement.[7]
This newsletter is for informational purposes only and does not constitute investment advice. Market data is sourced from multiple verified platforms and cross-validated as per our editorial standards. Investors should conduct independent research and consult financial advisors before making investment decisions. Oorjita FinAI Services is not liable for any investment decisions based on this content. Markets are subject to volatility and past performance does not guarantee future results.
This research is for information and education only and is not investment advice. Figures may be provisional. Oorjita.AI and its authors may hold positions in securities mentioned. Please consult a SEBI-registered investment adviser before making investment decisions. Published Friday, 26 September 2025, 8:18 AM IST.
All four layers aligned bearish. A/D = capitulation breadth.
Morning's Bear call was directionally validated, but the intraday recovery depth was underestimated. The market found its panic floor exactly where the morning brief mapped it — and then bounced.
Despite flat index performance, more stocks declined (1672) than advanced (1494), indicating weak internal market strength. This suggests the market move was concentrated in a few heavyweight stocks.
